tiprankstipranks
Trending News
More News >
Bachem Holding AG Class B (CH:BANB)
:BANB
Advertisement

Bachem Holding AG (BANB) AI Stock Analysis

Compare
4 Followers

Top Page

CH:BANB

Bachem Holding AG

(LSE:BANB)

Rating:72Outperform
Price Target:
CHF62.00
▼(-16.72%Downside)
Bachem Holding AG benefits from strong financial performance, highlighted by robust growth and profitability. Technical indicators suggest upward momentum, although potential overbought conditions could pose a risk. The high P/E ratio implies possible overvaluation, balanced by a solid financial foundation.

Bachem Holding AG (BANB) vs. iShares MSCI Switzerland ETF (EWL)

Bachem Holding AG Business Overview & Revenue Model

Company DescriptionBachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
How the Company Makes MoneyBachem Holding AG generates revenue primarily through the manufacturing and sale of peptides and oligonucleotides. These products are crucial for pharmaceutical companies engaged in drug discovery and development. The company's revenue streams include custom synthesis, catalog products, and active pharmaceutical ingredients (APIs). Bachem collaborates with pharmaceutical companies and research institutions, providing them with tailored solutions that support their R&D efforts. The company's strong market position and expertise in peptide chemistry enable it to secure long-term contracts and partnerships, contributing significantly to its earnings. Additionally, Bachem benefits from the growing demand for innovative therapeutics and personalized medicine, which drives the need for its specialized products.

Bachem Holding AG Financial Statement Overview

Summary
Bachem Holding AG demonstrates strong financial performance with consistent revenue growth, stable gross profit margins, and healthy net profit margins. The balance sheet reflects low leverage and a robust capital structure, while cash flow management is strong despite recent high capital expenditures impacting free cash flow.
Income Statement
85
Very Positive
Bachem Holding AG has shown a strong revenue growth rate with revenues increasing consistently year over year. The gross profit margin is stable, indicating good control over production costs. Net profit margins are healthy, supported by increasing net income over the past few years. EBIT and EBITDA margins are strong, showcasing efficient operations. The company has demonstrated solid growth and profitability in the medical pharmaceuticals sector.
Balance Sheet
80
Positive
The company maintains a low debt-to-equity ratio, reflecting low leverage and financial stability. The return on equity is robust, indicating effective use of equity to generate profits. The equity ratio is high, underscoring a strong capital structure. Bachem has increased its total assets significantly, primarily funded by equity, which reduces potential risks associated with high leverage.
Cash Flow
75
Positive
Bachem Holding AG exhibits strong operating cash flow relative to net income, indicating effective cash generation from operations. However, the free cash flow has been negative recently due to high capital expenditures, which could limit liquidity in the short term. Despite this, the company's investment in growth seems to be strategically driven.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue605.26M577.32M531.74M503.23M402.00M
Gross Profit182.56M176.96M171.28M166.73M128.91M
EBITDA178.76M163.28M157.08M156.47M121.72M
Net Income120.25M111.86M100.68M114.68M78.06M
Balance Sheet
Total Assets1.92B1.68B1.38B1.30B710.88M
Cash, Cash Equivalents and Short-Term Investments95.20M298.53M268.43M442.36M23.50M
Total Debt290.00K401.00K691.00K20.86M107.55M
Total Liabilities531.88M362.36M214.21M177.50M235.17M
Stockholders Equity1.39B1.32B1.17B1.12B475.71M
Cash Flow
Free Cash Flow-138.30M-18.54M-49.76M-19.66M45.53M
Operating Cash Flow146.32M249.86M92.59M97.16M114.63M
Investing Cash Flow-148.88M-170.81M-63.17M-469.13M-69.31M
Financing Cash Flow-61.26M48.69M-86.93M437.58M-42.66M

Bachem Holding AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price74.45
Price Trends
50DMA
56.01
Positive
100DMA
53.33
Positive
200DMA
57.80
Positive
Market Momentum
MACD
2.88
Negative
RSI
80.71
Negative
STOCH
81.18
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BANB, the sentiment is Positive. The current price of 74.45 is above the 20-day moving average (MA) of 59.30, above the 50-day MA of 56.01, and above the 200-day MA of 57.80, indicating a bullish trend. The MACD of 2.88 indicates Negative momentum. The RSI at 80.71 is Negative, neither overbought nor oversold. The STOCH value of 81.18 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:BANB.

Bachem Holding AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
CHF5.58B41.6010.07%1.14%17.34%18.15%
52
Neutral
$7.65B0.16-63.14%2.08%16.38%0.82%
CHF1.06B19.2311.46%0.05%
$5.41B27.1118.36%0.03%
$2.67B34.444.84%<0.01%
77
Outperform
CHF4.34B23.89
2.62%4.67%-35.91%
62
Neutral
CHF817.52M
3.15%62.88%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CH:BANB
Bachem Holding AG
72.65
-3.27
-4.31%
GB:0RGI
COSMO Pharmaceuticals N.V.
62.60
-6.86
-9.88%
SGFEF
Siegfried Holding AG
114.35
11.58
11.27%
TCHBF
Tecan Group AG
207.25
-154.74
-42.75%
CH:PPGN
PolyPeptide Group AG
24.50
-4.35
-15.08%
CH:GALE
Galenica AG
87.00
12.80
17.25%

Bachem Holding AG Corporate Events

Bachem Reports Robust Growth and Expansion Plans for 2025
Jul 24, 2025

Bachem Holding AG reported a strong financial performance in the first half of 2025, with group sales reaching CHF 313.0 million, marking a 30.2% increase compared to the previous year. The company also saw a significant rise in EBITDA to CHF 91.0 million, reflecting a 64.0% increase. Bachem is investing heavily in expanding its production capacity, with more than CHF 400 million planned for 2025, and aims for over CHF 1 billion in revenue by 2026. The expansion includes the development of a new production site in Sisslerfeld, Switzerland, and the continued enhancement of existing facilities. These strategic moves are expected to bolster Bachem’s market position and meet the growing demand for its products.

The most recent analyst rating on (CH:BANB) stock is a Buy with a CHF100.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.

Bachem Mourns the Passing of Founder Peter Grogg
Jun 3, 2025

Bachem mourns the loss of its founder, Dr. h.c. Peter Grogg, who passed away at 83. Grogg, who founded the company in 1971, was instrumental in transforming Bachem into a world leader in peptide synthesis, leaving a significant mark on the firm and Swiss economic history. His leadership spanned over three decades, during which he served as CEO and later as chairman of the board. The announcement highlights the deep impact Grogg had on Bachem’s operations and its standing in the industry.

The most recent analyst rating on (CH:BANB) stock is a Buy with a CHF100.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.

Bachem’s AGM 2025 Approves Board Proposals and Dividend
Apr 30, 2025

Bachem Holding AG announced that its Annual General Meeting 2025 approved all proposals from the Board of Directors, including a dividend of CHF 0.85 per share, to be paid on May 7, 2025. The meeting also saw the re-election of the President and Board members, the election of Dr. Simone Wyss Fedele to the Board, and the approval of various financial and sustainability reports. Forvis Mazars SA was appointed as the auditor for 2025. This approval reflects strong shareholder support and positions Bachem for continued stability and growth in the pharmaceutical and biotech sectors.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025